Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of...
Patent
1996-07-03
2000-12-05
Eisenschenk, Frank C.
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
4352351, 4353201, 4241991, 4242331, 536 241, 536 231, 514 44, A61K 39235, C07H 2104, C07K 14075, C12N 516
Patent
active
061565679
ABSTRACT:
Recombinant adenoviruses, methods of making them, uses for them, including in immunological, immunogenic, vaccine or therapeutic compositions, or, as a vector for cloning, replicating or expressing DNA and methods of using the compositions and vector, expression products from them, and uses for the expression products are provided. More particularly, recombinant canine adenoviruses (CAV) and methods of making them, uses for them, expression products from them, and uses for the expression products, including recombinant CAV2 viruses are provided. Additionally, truncated promoters, expression cassettes containing the promoters, and recombinant viruses and plasmids containing the promoters or expression cassettes are provided.
REFERENCES:
patent: 4963481 (1990-10-01), deVilliers
patent: 5122458 (1992-06-01), Post et al.
patent: 5273876 (1993-12-01), Hock et al.
patent: 5585237 (1996-12-01), Oppermann et al.
patent: 5616326 (1997-04-01), Spibey
patent: 5641662 (1997-06-01), Debs et al.
Ablett, R.E. and L.A. Baker. 1960. Veterinary Record, 72, 1202.
Bass, E.P., M.A. Gill and W.H. Beckenhauer. 1980. Evaluation of canine adenovirus type 2 as a replacement for infectious canine hepatatis vaccine. J. Am. Vet. Med. Assoc., 177, 234-242.
Bett, A.J., L. Prevec and F.L. Graham. 1993. Packaging capacity and stability of human adenovirus type 5 vectors. J. Virol., 67, 5911-5921.
Boshart, M., F. Weber, G. Jahn, K. Dorsh-Hasler, B. Fleckenstein and W. Schaffner. 1985. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell, 41, 521-530.
Both, G.W. , L.J. Lockett, V. Janardhana, S.J. Edwards, A.R. Bellamy, F.L. Graham, L. Prevec and M.E. Andrew. 1993. Protective immunity to rotavirus-induced diarrhoea is passively transferred to newborn mice from naive dams vaccinated with single dose of a recombinant adenovirus expressing rotavirus VP7sc. Virology, 193, 940-950.
Breker-Klassen, M., Yoo, D., Mittal, S.K., Sorden, S.D., Haines, D.M. and L.A. Babiuk. 1995. Recombinant type 5 adenovirus expressing bovine parainfluenza virus type 3 glycoproteins protect Sigmodon hispidus cotton rat from bovine parainfluenza virus type 3 infection. J. Virol., 69, 4308-4315.
Cavanagh, H.M.A., C.F. Gallagher and N. Spibey. 1991. A mutant of canine adenovirus type 2 with a duplication of the E1a region exhibits altered expression of early region 4. J. Gen. Virol., 72, 2121-2127.
Chanda, P.K., Natuk, R.J., B.B. Mason, B.M. Bhat, L. Greenberg, S.K. Dheer, K.L. Molnar-Kimber, S. Mizutani, M.D. Lubeck, A.R. Davis and P.P. Hung. 1990. High level expression of the envelope glycoprotein of the human immunodeficiency virus type I in presence of rev gene using helper-independent adenovirus type 7 recombinants. Virology, 175, 535-547.
Chengalvala, M., M.D. Lubeck, A.R. Davis, S. Mizutani, K. Molnar-Kimber, J. Morin, and P.P. Hung. 1991. Evaluation of adenovirus type 4 and type 7 recombinant hepatitis B vaccines in dogs. Vaccine, 9, 485-490.
Chengalvala, M.V. , B.M. Bhat, R. Bhat, M.D. Lubeck, S. Mizutani, A.R. Davis and P.P. Hung. 1994. Immunogenicity of high expression adenovirus-hepatatis B virus recombinant vaccines in dogs. J. Gen. Virol., 75, 125-131.
Danskin, D. 1973. Isolation of canine adenovirus A26/61 (Toronto) using canine kidney (MDCK) cell line. The Veterinary Record, 126-127.
Darteil, R., Bublot, M., Laplace, E., J.-F. Bouquet, J.-C. Audonnet and M. Riviere. 1995. Herpesvirus of turkey recombinant viruses expressing infectious bursal disease virus (IBDV) VP2 immunogen induce protection against an IBDV virulent challenge in chickens. Virology 211, 481-490.
Dewar, R.L. , V. Natarajan, M.B. Vasudevachari and N.P. Salzman. 1989. Synthesis and processing of human immunodeficiency virus type 1 envelope proteins encoded by recombinant human adenovirus. J. Virol. , 63, 129-136.
Ditchfield, J., L.W. MacPerson and A. Zbitnew. 1962. Association of a canine adenovirus (Toronto A26/61) with an outbreak of laryngotracheitis ("kennel cough"). Can. Vet. Jour., 3, 238-247.
Dorsch-Hasler, K., G.M. Keil, F. Weber, M. Jasin, W. Schaffner and U.H. Koszinowski. 1985. A long and complex enhancer activates transcription of the gene coding for the highly abundant early mRNA in murine cytomegalovirus. Proc. Natl. Acad. Sci., 82, 8325-8329.
Edbauer, C., R. Weinberg, J. Taylor, A. Rey-Senelonge, J-F. Bouquet, P. Desmettre and E. Paoletti. 1990. Protection of chickens with a recombinant fowlpox virus expressing the newcastle disease virus hemagglutinin-neuraminidase gene. Virology, 179, 901-904.
Eloit, M. , P. Gilardi-Hebenstreit, B. Toma and M. Perricaudet. 1990. Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gp50 and its use as a live vaccine. J. Gen. Virol., 71, 2425-2431.
Fairchild, G.A. and D. Cohen. 1969. Serological study of a canine adenovirus (Toronto A26/61) infection in dogs. Am. J. Vet. Res., 30, 923-928.
Gallichan, W.S., D.C. Johnson, F.L. Graham and K.L. Rosenthal. 1993. Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B. J. of Infect. Dis. 168, 622-629.
Garcia-Sastre, A. and P. Palese. 1995. Influenza virus vectors. Biologicals, 23, 171-178.
Gillard, S., Spehner, D., Drillien, R., and Kirn, A., Proc. Natl. Acad. Sci. USA 83, 5573-5577 (1986).
Goebel, S.J., Johnson, G.P., Perkus, M.E., Davis, S.W., Winslow, J.P., Paoletii, E., Virology 179, 247-266 (1990a).
Goebel, S.J., G.P. Johnson, M.E. Perkus, S.W. Davis, J.P. Winslow and E. Paoletti, Virology 179, 517-563 (1990b).
Ginsberg, H.S. , U. Lundholm-Beauchamp, R.L. Horswood, B. Pernis, W.S.M. Wold, R.M. Chanock and G.A. Prince. 1989. Role of early region 3 (E3) in pathogenesis of adenovirus disease. Proc. Natl. Acad. Sci. USA, 86, 3823-3827.
Gibard, M., R. Altmeyer, S. van der Werf, C. Wychowski and A. Martin. 1995. The use of picornaviruses as vectors for the engineering of live recombinant vaccines. Biologicals, 23, 165-169.
Gorman, C.M., D. Gies, G. McCray and M. Huang. 1989. The human cytomegalovirus major immediate early promoter can be trans-activated by adenovirus early proteins. Virology, 171, 377-385.Graham, F.L. , L.A. Prevec, M. Scheider, G. Ghosh-Choudhury, M. McDermott, and D.C. Johnson. 1988. Cloning and expression of glycoprotein genes in human adenovirus vectors. In: Technological Advances in Vaccine Development, 243-253.
Graham, F. L., J. Smiley, W. C. Russell and R. Nairn. 1977. Characteristics of a human cell line transformed by human adenovirus 5. J. Gen. Virol., 36, 59-72.
Graham, F. L., J. Smiley, W.C. Russel and Nairn. 1977. Characteristics of a human cell line transformed by human adenovirus 5. J. Gen. Virol, 36, 59-72.
Grand, R. J. A. 1987. The structure and function of the adenovirus early region 1 proteins. Biochem. J. , 241, 25-38.
Haddada, H., B. Klonjkowski and M. Perricaudet. 1994. Adenoviral vectors of animal origin and use in gene therapy. Patent # W094/26914.
Haj-Ahmad, Y. and F.L. Graham. 1986. Development of a helper-independent human adenovirus vector and its use in the transfer of herpes simplex virus thymidine kinase gene. J. Virol., 57, 267-274.
Hsu, K.-H.L., M.D. Lubeck, B.M. Bhat, R.A. Bhat, B. Kostek, B.H. Selling, S. Mizutani; A.R. Davis and P.P. Hung. 1994. Efficacy of adenovirus-vectored syncytial virus vaccines in a new ferret model. Vaccine, 12, 607-612.
Imler, J-L. 1995. Adenovirus vectors as recombinant viral vaccines. Vaccine, 13, 1143-1151.
Imperiale, M., G. Akusjarvi and K. Leppard. 1995. Post-transcriptional control of adenovirus gene expression. Curr. Top. Microbiol. Immunol., 199, 139-171.
Johnson, D.C., G. Ghosh-Choudhury, J.R. Smiley, L. Fallis and F.L. Graham. 1988. Abundant expression of herpes simplex virus glycoprotein gB using an adenovirus vector. Virology, 164, 1-14.
Jouvenne, P., M. Dion and C. Hamelin. 1987. Cloning, physical mapping and cross-hybridization of the canine adenovirus types 1 and 2 genomes. Gene, 60, 21-28.
Kelly, T.J., Jr. and A.M. Lewis, Jr. 1973. Use of nondefective adenovirus-simian virus 40 hybrids for mapping the simian v
Bui Phuong T.
Eisenschenk Frank C.
Frommer William S.
Kowalski Thomas J.
Merial
LandOfFree
Truncated transcriptionally active cytomegalovirus promoters does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Truncated transcriptionally active cytomegalovirus promoters, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Truncated transcriptionally active cytomegalovirus promoters will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-960674